SRTA
Strata Critical Medical, Inc
Strata Critical Medical, Inc historical holders
total: 1
Third Point Strata Critical Medical, Inc transactions over time
- Total transactions:
- 1
- New positions:
- 1
- Held since:
- 2025 Q3
- Held for:
- 3 quarters
- Latest activity:
- 2025 Q3
Daniel Loeb has been an institutional investor in Strata Critical Medical, Inc (SRTA) since 2025 Q3. According to 2026 Q1 report, Daniel Loeb holds 5,000,000 shares with a market value of roughly $20.90M representing 1.00% of their equity portfolio. The fund/company first acquired SRTA in 2025 Q3, initially purchasing about 5.00M shares.
Does Daniel Loeb still hold SRTA?
Yes, Daniel Loeb continues to hold Strata Critical Medical, Inc (SRTA). According to their 2026 Q1 report, they maintain a position of 5,000,000 shares valued at approximately $20.90M, representing 1.00% of their equity portfolio.
When did Daniel Loeb first invest in SRTA?
Daniel Loeb first invested in Strata Critical Medical, Inc (SRTA) in 2025 Q3 at the reported quarter-end price of $5.06 per share, acquiring 5,000,000 shares in their initial purchase.
What is Daniel Loeb's average cost basis for SRTA?
Based on historical transaction data, Daniel Loeb's estimated cost basis for Strata Critical Medical, Inc (SRTA) is approximately $5.06 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $5.06
SRTA transactions history by Third Point
1 result
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2025 Q3
|
0.30%
|
5,000,000
|
$5.06
|
$25,300,000
|
new
|
+0.3%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.